In HER2 positive breast cancer, vaccine reduces recurrence
the ONA take:
According to results presented by The University of Texas MD Anderson Cancer Center at the 2014 American Society of Clinical Oncology's (ASCO) Breast Cancer Symposium in San Francisco, California, GP2, a novel immunotherapy breast cancer vaccine, has demonstrated a reduction in recurrence in patients with breast cancer. Specifically, GP2 reduced recurrence rates by 57% in women with breast cancer.
Furthermore, patients with human epidermal growth factor receptor 2 (HER2) +3, the highest overexpression of HER2, experienced no cancer recurrences after receiving the vaccine after trastuzumab therapy.
In the randomized, phase 2 study, 89 patients with different levels of HER2 received granulocyte/macrophage colony-stimulating factor (GM-CSF) and the GP2 vaccine, while 91 patients received only GM-CSF. The vaccine administration consisted of six monthly inoculations injected subcutaneously, followed by a booster shot given every 6 months for 2 years. Participants were monitored for approximately 3 years.
In the experimental group, 88% of women achieved disease-free survival for the duration of the study compared with 81% of women in the control group, equating to a 37% reduction in recurrence.
GP2 has demonstrated a reduction in recurrence in patients with breast cancer.
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. These findings were presented by The University of Texas MD Anderson Cancer Center at the 2014 American Society of Clinical Oncology's Breast Cancer Symposium in San Francisco.
One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57%. Further, women with the highest overexpression of HER2 (known as HER2 +3) had no cancer recurrences when they were administered the vaccine after completing trastuzumab (Herceptin), a type of immunotherapy drug known as a monoclonal antibody. HER2 is an oncoprotein that promotes tumor growth and is expressed to some extent in 75-80% of breast cancers.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|